ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 914,65
-0,88%
Dow Jones
38 225,66
0,85%
DAX
17 896,50
-0,14%
Brent Oil
83,775
0,17%
Bitcoin
59 730,64
1,03%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Entera Bio Ltd (ENTX)

  7. Entera Bio Ltd (ENTX) Actualités

ENTX Entera Bio Ltd

2,09
0,09 (4,50%)
03 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Entera Bio Ltd ENTX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,09 4,50% 2,09 01:56:47
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
2,05 1,93 2,12 2,09 2,00
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
08/4/202414:30GLOBEEntera Bio Announces Publication of Oral PTH(1-34) Peptide..
26/3/202413:30GLOBEEntera Bio Announces Key Regulatory Milestone for Oral..
20/3/202413:00GLOBEEntera Bio Announces Robust Pharmacokinetic Data for..
08/3/202422:25EDGAR2Form S-8 - Securities to be offered to employees in employee..
08/3/202422:12EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
08/3/202422:10EDGAR2Form 8-K - Current report
08/3/202422:05GLOBEEntera Bio Announces Full Year 2023 Financial Results and..
04/3/202414:30EDGAR2Form 8-K - Current report
04/3/202414:30GLOBEEntera Bio Regains Compliance with Nasdaq Minimum Bid Price..
15/2/202423:10EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
15/2/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
14/2/202412:05EDGAR2Form S-3/A - Registration statement under Securities Act of..
02/2/202422:19EDGAR2Form 8-K - Current report
02/2/202422:17EDGAR2Form S-3 - Registration statement under Securities Act of..
30/1/202414:30GLOBEEntera Bio to Present at the Oppenheimer 34th Annual..
16/1/202414:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/1/202400:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202400:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202422:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202422:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202414:00EDGAR2Form 8-K - Current report
27/12/202314:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/12/202314:00EDGAR2Form 8-K - Current report
26/12/202314:00GLOBEEntera Bio Announces Closing of Private Placement - Extends..
29/11/202314:30GLOBEInterim Results from Ongoing Clinical Study Confirm EB613..
14/11/202313:30GLOBEEntera Bio Reports Q3 2023 Financial Results, Highlights..
09/11/202320:30GLOBEEntera Bio Reports Key Milestone Relating to Oral PTH (1-34)..
16/10/202314:00GLOBEEntera Bio Reports Rapid Pharmacodynamic (PD) Response and..
14/9/202323:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/9/202323:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/9/202322:05EDGAR2Form 8-K - Current report
12/9/202314:30GLOBEEntera Bio Announces Collaboration with OPKO Biologics to..
05/9/202314:00GLOBEEntera Bio to Participate in Upcoming Investor Conferences
24/8/202314:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/8/202314:11EDGAR2Form 3 - Initial statement of beneficial ownership of..
22/8/202315:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/8/202314:30GLOBEEntera Bio to Present Two Abstracts on its First-in-Class,..
15/8/202322:10EDGAR2Form DEF 14A - Other definitive proxy statements
11/8/202322:19EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/8/202322:16EDGAR2Form 8-K - Current report
11/8/202322:05GLOBEEntera Bio Announces Q2 2023 Financial Results and Corporate..
30/6/202322:06EDGAR2Form 8-K - Current report
07/6/202313:30GLOBEEntera Bio Adds Sanofi Commercial Leader, Haya Taitel to its..
05/5/202322:05GLOBEEntera Bio Announces Q1 2023 Financial Results and Corporate..

Dernières Valeurs Consultées

NASDAQ
ENTX
Entera Bio
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés